Blockade of type A, not type B, CCK receptors attenuates satiety actions of exogenous and endogenous CCK

T. H. Moran, P. J. Ameglio, Gary J. Schwartz, P. R. McHugh

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

Recent work has suggested a role for an endogenous release of cholecystokinin (CCK) acting at either type A or type B CCK receptors in the control of food intake. In an effort to investigate whether the mechanisms by which exogenously administered and endogenously released CCK inhibits food intake are similar and depend upon interactions with either type A or type B CCK receptors, we examined in rats the ability of the type A (L 364718) and type B (L 365260) CCK receptor antagonists to 1) block the inhibition of glucose consumption produced by an intraperitoneal injection of 4 μg/kg of CCK and 2) increase glucose consumption in the absence of exogenous CCK after a 6-h daytime deprivation. Increasing dosages (10-100 μg/kg) of the type A CCK antagonist resulted in a dose-related blockade of the inhibition of intake produced by CCK, and the 100 μg/kg dose of the A antagonist significantly increased glucose intake above baseline levels. In contrast, no dose (10-1,000 μg/kg) of the B antagonist blocked the inhibitory action of exogenous CCK at any time point. In the absence of exogenous CCK, the 32 and 100 μg/kg doses of L 364718 increased intake above baseline levels. No dose (3.2-320 μg/kg) of the type B antagonist, L 365260, affected intake in this paradigm. These results suggest that the mediation of the feeding-inhibitory effects of exogenous and endogenous CCK are similar and depend upon activation of type A CCK receptors.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume262
Issue number1 31-1
StatePublished - 1992
Externally publishedYes

Fingerprint

Cholecystokinin B Receptor
Cholecystokinin
Devazepide
Glucose
Eating
Cholecystokinin A Receptor
Cholecystokinin Receptors
Intraperitoneal Injections

Keywords

  • Food intake
  • L 364718
  • L 365260

ASJC Scopus subject areas

  • Physiology

Cite this

@article{96fbea7dc6214ef0b5ec09a2453d137c,
title = "Blockade of type A, not type B, CCK receptors attenuates satiety actions of exogenous and endogenous CCK",
abstract = "Recent work has suggested a role for an endogenous release of cholecystokinin (CCK) acting at either type A or type B CCK receptors in the control of food intake. In an effort to investigate whether the mechanisms by which exogenously administered and endogenously released CCK inhibits food intake are similar and depend upon interactions with either type A or type B CCK receptors, we examined in rats the ability of the type A (L 364718) and type B (L 365260) CCK receptor antagonists to 1) block the inhibition of glucose consumption produced by an intraperitoneal injection of 4 μg/kg of CCK and 2) increase glucose consumption in the absence of exogenous CCK after a 6-h daytime deprivation. Increasing dosages (10-100 μg/kg) of the type A CCK antagonist resulted in a dose-related blockade of the inhibition of intake produced by CCK, and the 100 μg/kg dose of the A antagonist significantly increased glucose intake above baseline levels. In contrast, no dose (10-1,000 μg/kg) of the B antagonist blocked the inhibitory action of exogenous CCK at any time point. In the absence of exogenous CCK, the 32 and 100 μg/kg doses of L 364718 increased intake above baseline levels. No dose (3.2-320 μg/kg) of the type B antagonist, L 365260, affected intake in this paradigm. These results suggest that the mediation of the feeding-inhibitory effects of exogenous and endogenous CCK are similar and depend upon activation of type A CCK receptors.",
keywords = "Food intake, L 364718, L 365260",
author = "Moran, {T. H.} and Ameglio, {P. J.} and Schwartz, {Gary J.} and McHugh, {P. R.}",
year = "1992",
language = "English (US)",
volume = "262",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "1 31-1",

}

TY - JOUR

T1 - Blockade of type A, not type B, CCK receptors attenuates satiety actions of exogenous and endogenous CCK

AU - Moran, T. H.

AU - Ameglio, P. J.

AU - Schwartz, Gary J.

AU - McHugh, P. R.

PY - 1992

Y1 - 1992

N2 - Recent work has suggested a role for an endogenous release of cholecystokinin (CCK) acting at either type A or type B CCK receptors in the control of food intake. In an effort to investigate whether the mechanisms by which exogenously administered and endogenously released CCK inhibits food intake are similar and depend upon interactions with either type A or type B CCK receptors, we examined in rats the ability of the type A (L 364718) and type B (L 365260) CCK receptor antagonists to 1) block the inhibition of glucose consumption produced by an intraperitoneal injection of 4 μg/kg of CCK and 2) increase glucose consumption in the absence of exogenous CCK after a 6-h daytime deprivation. Increasing dosages (10-100 μg/kg) of the type A CCK antagonist resulted in a dose-related blockade of the inhibition of intake produced by CCK, and the 100 μg/kg dose of the A antagonist significantly increased glucose intake above baseline levels. In contrast, no dose (10-1,000 μg/kg) of the B antagonist blocked the inhibitory action of exogenous CCK at any time point. In the absence of exogenous CCK, the 32 and 100 μg/kg doses of L 364718 increased intake above baseline levels. No dose (3.2-320 μg/kg) of the type B antagonist, L 365260, affected intake in this paradigm. These results suggest that the mediation of the feeding-inhibitory effects of exogenous and endogenous CCK are similar and depend upon activation of type A CCK receptors.

AB - Recent work has suggested a role for an endogenous release of cholecystokinin (CCK) acting at either type A or type B CCK receptors in the control of food intake. In an effort to investigate whether the mechanisms by which exogenously administered and endogenously released CCK inhibits food intake are similar and depend upon interactions with either type A or type B CCK receptors, we examined in rats the ability of the type A (L 364718) and type B (L 365260) CCK receptor antagonists to 1) block the inhibition of glucose consumption produced by an intraperitoneal injection of 4 μg/kg of CCK and 2) increase glucose consumption in the absence of exogenous CCK after a 6-h daytime deprivation. Increasing dosages (10-100 μg/kg) of the type A CCK antagonist resulted in a dose-related blockade of the inhibition of intake produced by CCK, and the 100 μg/kg dose of the A antagonist significantly increased glucose intake above baseline levels. In contrast, no dose (10-1,000 μg/kg) of the B antagonist blocked the inhibitory action of exogenous CCK at any time point. In the absence of exogenous CCK, the 32 and 100 μg/kg doses of L 364718 increased intake above baseline levels. No dose (3.2-320 μg/kg) of the type B antagonist, L 365260, affected intake in this paradigm. These results suggest that the mediation of the feeding-inhibitory effects of exogenous and endogenous CCK are similar and depend upon activation of type A CCK receptors.

KW - Food intake

KW - L 364718

KW - L 365260

UR - http://www.scopus.com/inward/record.url?scp=0026522625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026522625&partnerID=8YFLogxK

M3 - Article

C2 - 1733339

AN - SCOPUS:0026522625

VL - 262

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 1 31-1

ER -